Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Receivables: 2018-2025

Historic Receivables for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $3.5 million.

  • China SXT Pharmaceuticals' Receivables fell 72.24% to $119.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $548.0 billion, marking a year-over-year decrease of 35.92%. This contributed to the annual value of $3.5 million for FY2025, which is 11.57% up from last year.
  • China SXT Pharmaceuticals' Receivables amounted to $3.5 million in FY2025, which was up 11.57% from $3.1 million recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Receivables registered a high of $6.0 million during FY2021, and its lowest value of $3.1 million during FY2023.
  • In the last 3 years, China SXT Pharmaceuticals' Receivables had a median value of $3.1 million in 2024 and averaged $3.2 million.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Receivables increased by 12.22% in 2021, and later tumbled by 33.69% in 2023.
  • Yearly analysis of 5 years shows China SXT Pharmaceuticals' Receivables stood at $6.0 million in 2021, then declined by 22.72% to $4.7 million in 2022, then slumped by 33.69% to $3.1 million in 2023, then increased by 1.03% to $3.1 million in 2024, then increased by 11.57% to $3.5 million in 2025.